Bain dou­bles down on Tony Coles’ quest to get a late-stage Parkin­son’s drug through to mar­ket

Cerev­el Ther­a­peu­tics had a charmed start to its life with the back­ing of fi­nan­cial gi­ant Bain Cap­i­tal and a clutch of for­mer Pfiz­er as­sets to work with. Now, ex­tend­ing its re­la­tion­ship with Bain, Cerev­el has snagged an­oth­er big check to race its Parkin­son’s dis­ease can­di­date through late-stage stud­ies and on to mar­ket.

Bain and No­vaQue­st will drop $125 mil­lion in non-di­lu­tive fund­ing to dri­ve Cerev­el’s Phase III pro­gram for Parkin­son’s drug tava­padon, with up to $531 mil­lion in fu­ture mile­stones at stake, the biotech said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER